Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19350115 | 0.89 | SMN1; SMN2 (0.32) | SMN1; SMN2 | |
| SCHEMBL575208 | 0.84 | SMN1; SMN2 (0.38) | SMN1; SMN2HTTCA1CA2CA9 | |
| SCHEMBL19348617 | 0.78 | MEN1 (0.49) | — | |
| SCHEMBL20017131 | 0.77 | ALDH1A1 (0.42) | SMN1; SMN2HTTCA1CA2CA9 | |
| SCHEMBL576398 | 0.77 | SMN1; SMN2 (0.35) | SMN1; SMN2HTTCA1CA2CA9 | |
| SCHEMBL575242 | 0.77 | SMN1; SMN2 (0.35) | SMN1; SMN2HTTCA1CA2CA9 | |
| SCHEMBL23722714 | 0.75 | HTT (0.34) | SMN1; SMN2HTTCA1CA2CA9 | |
| SCHEMBL16424544 | 0.75 | SMN1; SMN2 (0.38) | SMN1; SMN2HTTCA1CA2CA9 | |
| SCHEMBL575246 | 0.75 | SMN1; SMN2 (0.34) | SMN1; SMN2HTTCA1CA2CA9 | |
| SCHEMBL575073 | 0.75 | SMN1; SMN2 (0.34) | SMN1; SMN2HTTCA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3222624-B1 | IMIDIC ACID COMPOUND HAVING DIVALENT ANION AND PROCESS FOR PRODUCING THE SAME | CENTRAL GLASS CO LTD (JP) | 2019-11-06 | — | — | EP | disclosed |
| US-10287165-B2 | Imidic acid compound having divalent anion and process for producing the same | CENTRAL GLASS CO., LTD. (JP) | 2019-05-14 | — | — | US | disclosed |
| EP-3222624-A1 | IMIDIC ACID COMPOUND HAVING DIVALENT ANION AND PROCESS FOR PRODUCING THE SAME | Central Glass Co., Ltd. (JP) | 2017-09-27 | — | — | EP | disclosed |
| US-20170267528-A1 | IMIDIC ACID COMPOUND HAVING DIVALENT ANION AND PROCESS FOR PRODUCING THE SAME | CENTRAL GLASS CO., LTD. (JP) | 2017-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267528-A1 | IMIDIC ACID COMPOUND HAVING DIVALENT ANION AND PROCESS FOR PRODUCING THE SAME | CA2, CA6, CHRM1 | SMN1; SMN2 2964/4885HTT 4295/4885CA1 7/4885 |
| US-10287165-B2 | Imidic acid compound having divalent anion and process for producing the same | CA2, CA6, CHRM1 | SMN1; SMN2 2964/4885HTT 4295/4885CA1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.